NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $5.24 +0.15 (+2.95%) (As of 06:32 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Skye Bioscience Stock (NASDAQ:SKYE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$4.92▼$5.2850-Day Range$3.55▼$5.2452-Week Range$1.44▼$19.41Volume111,400 shsAverage Volume179,199 shsMarket Capitalization$158.97 millionP/E RatioN/ADividend YieldN/APrice Target$18.67Consensus RatingBuy Company OverviewSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Skye Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks32nd Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 32% of companies evaluated by MarketBeat, and ranked 843rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.06) to ($1.21) per share.Read more about Skye Bioscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.77% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Skye Bioscience has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.77% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Skye Bioscience has recently increased by 17.36%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.58 News SentimentSkye Bioscience has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Skye Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows12 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,750,352.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Stock News HeadlinesMarketBeat Week in Review – 10/7 - 10/11 (SKYE)Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earningsOctober 12, 2024 | marketbeat.comDon’t Sleep on Skye Bioscience—This Weight Loss Drug Could SoarSkye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.October 9, 2024 | marketbeat.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't IgnoreCheck out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.October 4, 2024 | marketbeat.comSkye Bioscience Appoints New Chairman for Strategic GrowthOctober 30 at 9:41 AM | markets.businessinsider.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.67 Average Target Price from BrokeragesOctober 30 at 1:51 AM | americanbankingnews.comSkye Bioscience names Grayson as Chairman of the BoardOctober 29 at 6:39 PM | markets.businessinsider.comSkye Bioscience Names Independent Director Paul Grayson as Chairman of the BoardOctober 29 at 6:39 PM | markets.businessinsider.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.72 at the start of the year. Since then, SKYE shares have increased by 92.6% and is now trading at $5.24. View the best growth stocks for 2024 here. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) posted its quarterly earnings results on Friday, August, 9th. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings8/09/2024Today10/31/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$18.67 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+269.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.83% Return on Assets-80.69% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-29.71Miscellaneous Outstanding Shares30,338,000Free Float29,428,000Market Cap$153.21 million OptionableOptionable Beta1.78 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:SKYE) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.